Interleukin-33 and Inflammatory Bowel Diseases: Lessons from Human Studies
Table 3
Studies evaluating the IL-33 receptor ST2 in inflammatory bowel diseases using human samples are listed chronologically with data regarding the assessed disease, method of analysis, and main results.
↑ST2 in IBD versus controls. Active UC > remission
NA
Colonic biopsies
ELISA WB IF
↑ST2s mRNA was observed in active UC versus CD and controls. In WB, ST2s was only detected in UC. ST2s/ST2L expression was ↑ in active UC. ↑ST2 is due to ↑ST2s expression
Observed loss of ST2 staining in the epithelium in UC patients with strong expression observed in the cytoplasm and in the apical surface of crypt epithelial cells
ST2 staining was found in the mucosa of UC and CD and in controls
ST2 is expressed by colonocytes and its expression is barely detectable among leukocytes in the lamina propria. Subepithelial infiltrates contained many ST2-positive cells in either active or nonactive IBD
qRT-PCR: quantitative polymerase chain reaction, IF: immunofluorescence, IHC: immunohistochemistry, WB: western blot, LPMC: lamina propria mononuclear cells, IEC: intestinal epithelial cells, (↑) increase, (↓) decrease, and (NA) nonapplicable.